These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20388407)

  • 41. Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers.
    Sandomenico A; Ruvo M
    Curr Med Chem; 2019; 26(11):1994-2050. PubMed ID: 30207211
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cripto localizes Nodal at the limiting membrane of early endosomes.
    Blanchet MH; Le Good JA; Oorschot V; Baflast S; Minchiotti G; Klumperman J; Constam DB
    Sci Signal; 2008 Nov; 1(45):ra13. PubMed ID: 19001664
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cripto-1 alters keratinocyte differentiation via blockade of transforming growth factor-beta1 signaling: role in skin carcinogenesis.
    Shukla A; Ho Y; Liu X; Ryscavage A; Glick AB
    Mol Cancer Res; 2008 Mar; 6(3):509-16. PubMed ID: 18337457
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth.
    Ishii H; Zahra MH; Takayanagi A; Seno M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567764
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulation of human Cripto-1 gene expression by TGF-beta1 and BMP-4 in embryonal and colon cancer cells.
    Mancino M; Strizzi L; Wechselberger C; Watanabe K; Gonzales M; Hamada S; Normanno N; Salomon DS; Bianco C
    J Cell Physiol; 2008 Apr; 215(1):192-203. PubMed ID: 17941089
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
    Kelly RK; Olson DL; Sun Y; Wen D; Wortham KA; Antognetti G; Cheung AE; Orozco OE; Yang L; Bailly V; Sanicola M
    Eur J Cancer; 2011 Jul; 47(11):1736-46. PubMed ID: 21458984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intercellular transfer regulation of the paracrine activity of GPI-anchored Cripto-1 as a Nodal co-receptor.
    Watanabe K; Salomon DS
    Biochem Biophys Res Commun; 2010 Dec; 403(1):108-13. PubMed ID: 21055389
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trop molecules as targets for anti-tumor immunotherapy in man.
    Alberti S
    Tumori; 2001; 87(6):S5-8. PubMed ID: 11989616
    [No Abstract]   [Full Text] [Related]  

  • 49. Identification of cripto-1 as a novel serologic marker for breast and colon cancer.
    Bianco C; Strizzi L; Mancino M; Rehman A; Hamada S; Watanabe K; De Luca A; Jones B; Balogh G; Russo J; Mailo D; Palaia R; D'Aiuto G; Botti G; Perrone F; Salomon DS; Normanno N
    Clin Cancer Res; 2006 Sep; 12(17):5158-64. PubMed ID: 16951234
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New solid tumor targets for therapeutic monoclonal antibodies.
    Papkoff J
    Expert Opin Ther Targets; 2007 May; 11(5):585-8. PubMed ID: 17465718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modulation of TGF-beta signaling by EGF-CFC proteins.
    Wechselberger C; Bianco C; Strizzi L; Ebert AD; Kenney N; Sun Y; Salomon DS
    Exp Cell Res; 2005 Nov; 310(2):249-55. PubMed ID: 16137677
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells.
    Wechselberger C; Ebert AD; Bianco C; Khan NI; Sun Y; Wallace-Jones B; Montesano R; Salomon DS
    Exp Cell Res; 2001 May; 266(1):95-105. PubMed ID: 11339828
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer.
    Zhong XY; Zhang LH; Jia SQ; Shi T; Niu ZJ; Du H; Zhang GG; Hu Y; Lu AP; Li JY; Ji JF
    Histopathology; 2008 Apr; 52(5):560-8. PubMed ID: 18312357
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line.
    Baldassarre G; Bianco C; Tortora G; Ruggiero A; Moasser M; Dmitrovsky E; Bianco AR; Ciardiello F
    Int J Cancer; 1996 May; 66(4):538-43. PubMed ID: 8635871
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decrypting the role of Cripto in tumorigenesis.
    Shen MM
    J Clin Invest; 2003 Aug; 112(4):500-2. PubMed ID: 12925690
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An evolving web of signaling networks regulated by Cripto-1.
    Nagaoka T; Karasawa H; Castro NP; Rangel MC; Salomon DS; Bianco C
    Growth Factors; 2012 Feb; 30(1):13-21. PubMed ID: 22149969
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nodal-dependant Cripto signaling in ES cells: from stem cells to tumor biology.
    Minchiotti G
    Oncogene; 2005 Aug; 24(37):5668-75. PubMed ID: 16123800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial--mesenchymal transition.
    Chen SC; Kung ML; Hu TH; Chen HY; Wu JC; Kuo HM; Tsai HE; Lin YW; Wen ZH; Liu JK; Yeh MH; Tai MH
    J Pathol; 2012 Oct; 228(2):158-69. PubMed ID: 22247069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Advance in biomarkers of lung cancer in diagnosis and targeted therapy].
    Zhang J; Liang ZY; Zeng X; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):564-7. PubMed ID: 20021976
    [No Abstract]   [Full Text] [Related]  

  • 60. Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors.
    Saeki T; Stromberg K; Qi CF; Gullick WJ; Tahara E; Normanno N; Ciardiello F; Kenney N; Johnson GR; Salomon DS
    Cancer Res; 1992 Jun; 52(12):3467-73. PubMed ID: 1596904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.